<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03877263</url>
  </required_header>
  <id_info>
    <org_study_id>1297556</org_study_id>
    <nct_id>NCT03877263</nct_id>
  </id_info>
  <brief_title>Comparing Specimen Collection Techniques to Screen for Sexually Transmitted Infections in Pregnant Women: A Pilot Study</brief_title>
  <official_title>Comparing Specimen Collection Techniques to Screen for Sexually Transmitted Infections in Pregnant Women: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OhioHealth</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OhioHealth</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to compare two specimen collection techniques (vaginal
      vs. endocervical swab) to screen for sexually transmitted infections in pregnant women.
      Either a physician or the patient may collect the vaginal specimen; the physician will
      collect the endocervical specimen during a standard-of-care pelvic exam. Each technique
      utilizes a specialized swab for specimen collection. We will used the Hologic Aptima C.
      trachomatis and N. gonorrhoeae detection assay to analyze both specimens.

      We hypothesize that the results from the physician-collected vaginal specimen will have
      equivalent outcomes those from the physician-collected endocervical specimen. If the
      techniques are equivalent for detecting infection, there may be an opportunity for cost
      saving and increased patient satisfaction with the vaginal technique, especially using
      patient-collected vaginal specimen collection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chlamydia trachomatis and Neisseria gonorrhoeae are the two most commonly reported infectious
      diseases in the United States. Their role in pregnancy-related comorbidities such as
      spontaneous abortion, preterm labor, chorioamnionitis, preterm premature rupture of
      membranes, and perinatal infection is complicated as data is conflicting. Many reports
      suggest increased risks of adverse pregnancy outcomes in the presence of C. trachomatis and
      N. gonorrhoeae infections. However, there are also several studies that have failed to
      demonstrate an increased risk. Despite conflicting reports, due to high prevalence of these
      infections and association with pregnancy-related co-morbidities, the Center for Disease
      Control (CDC) recommends screening for C. trachomatis and N. gonorrhoeae in high-risk
      populations at initiation of prenatal care, and again during the third trimester to ensure
      infections are treated quickly and resolved prior to birth.

      In the non-pregnant female population, there are many ways to screen for C. trachomatis and
      N. gonorrhoeae pelvic infections, including bacterial culture, direct fluorescent antibody
      testing, deoxyribonucleic acid (DNA) probe, enzyme immunoassay, or ribonucleic acid (RNA)
      amplification. These various testing modalities can be applied to urine, or vaginal or
      endocervical samplings. RNA assays and DNA probes are currently the least expensive and most
      accurate way of screening, and are therefore the most routinely used.

      At OhioHealth Doctors Hospital (DH) Women's Health Center, pregnant patients are screened for
      sexually transmitted infections (STI) using the Hologic Aptima Chlamydia trachomatis and the
      Neisseria gonorrhoeae assays, which are second generation nucleic acid amplification assays
      (NAATs). Samples are collected using the Hologic Aptima Unisex Specimen Collection Kit for
      Endocervical and Male Urethral Swab Specimens. These swabs are specifically designed for
      cervical swab collection techniques. Per standard of care at DH and CDC recommendations,
      patient endocervical swabs are collected at the patient's initial prenatal visit and during
      her third trimester appointment (approximately 36 week gestation) to test for infection.

      In non-pregnant women, the vaginal specimen collection kit has been shown to be just as
      effective at detecting pelvic infections of C. trachomatis and N. gonorrhea using RNA assays.
      There are many benefits of adopting the use of a vaginal specimen collection kit, as compared
      to endocervical collection. Vaginal sampling can be performed without a speculum exam in
      asymptomatic women. In addition to being a less invasive test, the vaginal swab may reduce
      testing costs, by eliminating the use of collection tools (such as disposable speculums) that
      are required during an endocervical collection; avoiding the endocervical collection
      procedure may also reduce the overall office visit time. Additionally, patients could be
      instructed to collect a vaginal sample themselves. This may increase patient satisfaction,
      privacy, and comfort. In fact, several publications have reported patient preference for a
      self-collected vaginal swab vs. an endocervical swab.

      Few studies have evaluated the used of vaginal or introital swabbing techniques for detection
      of infectious microorganisms during pregnancy, but the published data is favorable for the
      use of a vaginal swab. Thus, more data is needed to compare the use of vaginal vs.
      endocervical swabs to detect infections in pregnant women. The objective of this study is to
      compare detection of sexually transmitted infections in pregnant women by collecting samples
      using both the Hologic Aptima Vaginal Swab and the Unisex Specimen Collection Kit for
      Endocervical and Male Urethral Swab.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 12, 2019</start_date>
  <completion_date type="Anticipated">March 11, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 11, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Patients agreeing to participate in the study will be randomized by visit into a study group in a 1:1 fashion. Patients who participate during both their initial and third trimester (of pregnancy) will be randomized twice to a study group.
The randomization allocation schedule will be developed by biostatisticians from the OhioHealth Research &amp; Innovation Institute (OHRI), and will be hidden from the investigator until directly prior to enrollment to prevent bias. The clinical research coordinator will reveal the randomization allocation once patient is consented and enrolled into the study.
Due to the nature of the study, we cannot completed mask the investigator from the study group while taking the vaginal swabs.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the physician-collected vaginal swab outcomes to those from the physician-collected endocervical swab.</measure>
    <time_frame>12 months</time_frame>
    <description>Determine the rate of concordance for infection screening results between the physician collected vaginal and physician collected endocervical specimens in pregnant patients. Concordance will be defined as same results (whether positive or negative) on both methods.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the costs of medical supplies used during pelvic examinations.</measure>
    <time_frame>12 months</time_frame>
    <description>Compare the costs of medical supplies used in endocervical vs vaginal sample collection techniques.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Patient satisfaction following specimen collection.</measure>
    <time_frame>12 months</time_frame>
    <description>We will describe patient satisfaction following specimen collection using a patient-collected vaginal swab, a physician-collected vaginal swab, or a physician-collected endocervical swab.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Sexually Transmitted Diseases</condition>
  <arm_group>
    <arm_group_label>OB/GYN physician-collected vaginal swab</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients assigned to the physician-collected vaginal swab group will have their Vaginal swab for detection of STI collected by their obstetrics and gynecology (OB/GYN) physician.
The vaginal swabs will be collected first for all patients, to avoid any swab contact with lubricant. As standard of care, the physician will collect Endocervical swab for detection of STI for this group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient-collected vaginal swab</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients assigned to the patient-collected vaginal swab group will self-collect the Vaginal swab for detection of sexually transmitted infection (STI). Patients who self-collect will receive instructions from their OB/GYN physician and in paper form.
The vaginal swabs will be collected first for all patients, to avoid any swab contact with lubricant. As standard of care, the physician will collect Endocervical swab for detection of STI for this group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Endocervical swab for detection of STI</intervention_name>
    <description>After we collect the samples, they will be evaluated using the Hologic APTIMA Chlamydia trachomatis and Neisseria gonorrhoeae assays.</description>
    <arm_group_label>OB/GYN physician-collected vaginal swab</arm_group_label>
    <arm_group_label>Patient-collected vaginal swab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Vaginal swab for detection of STI</intervention_name>
    <description>After we collect the samples, they will be evaluated using the Hologic APTIMA Chlamydia trachomatis and Neisseria gonorrhoeae assays.
We will then compare the results from a vaginal vs. endocervical specimens within and between the groups</description>
    <arm_group_label>OB/GYN physician-collected vaginal swab</arm_group_label>
    <arm_group_label>Patient-collected vaginal swab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pregnant &amp; receiving prenatal care at Doctors Hospital Women's Health Center

          2. â‰¥16 years old

          3. Able to understand &amp; consent to study participation

          4. English speaking &amp; reading; if minor assent form is required, the parent or guardian
             must also be English speaking &amp; reading

        Exclusion Criteria:

          1. Females who are not pregnant.

          2. &lt;16 years old.

          3. Not english speaking &amp; reading; if minor assent form is required, the parent or
             guardian are not english speaking &amp; reading
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diana Topolnycky, DO</last_name>
    <role>Study Chair</role>
    <affiliation>Attending Physician</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Krista Jensen, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Resident Physician</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Krista Jensen, DO</last_name>
    <phone>(614) 566-4378</phone>
    <email>Krista.Jensen@ohiohealth.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laura Rush, RN, DVM, PhD</last_name>
    <phone>(614) 788-3864</phone>
    <email>Laura.Rush@ohiohealth.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>OhioHealth Doctors Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43228</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura J Rush, RN, DVM, PhD</last_name>
      <phone>614-788-3864</phone>
      <email>Laura.rush@ohiohealth.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>March 14, 2019</study_first_submitted>
  <study_first_submitted_qc>March 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2019</study_first_posted>
  <last_update_submitted>May 2, 2019</last_update_submitted>
  <last_update_submitted_qc>May 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chlamydia Trachomatis</keyword>
  <keyword>Neisseria gonorrhoeae</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sexually Transmitted Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>All study data will be collected using study-specific data abstraction sheets/data collection tools (e.g., REDCap or Excel). Only institutional review board (IRB)-approved variables will be collected. Electronic files will be stored on a password-protected computer, and paper files will be stored in a secure facility with limited access (the offices of the OhioHealth Research Institute). Desktop or mobile computers used for research purposes will be password-protected and encrypted. Data transmitted over the internet or via email will be encrypted.
All resulting data will be securely stored in electronic format according to OhioHealth policy; the data collection and storage processes will follow HIPAA guidelines in accordance to 45 Code of Federal Regulations (CFR) Part 160 &amp; 164, to protect both confidentiality and privacy of each participant. All protected health information (PHI) data will be released or destroyed per institution protocol.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

